The World Small Animal Veterinary Association (WSAVA) is pleased to announce a new partnership with Nannong Animal Pharmaceuticals Co. Ltd., a China-based company focused on the development of animal health and welfare products. Through this collaboration, Nannong joins WSAVA as a Bronze Partner, supporting our mission to advance the health and wellbeing of companion animals around the world.
As part of the partnership, Nannong will be supporting our WSAVA Pain Management Committee. Their engagement will help enhance the committee’s work in promoting best practices and raising awareness around pain assessment and treatment in small animals.
In addition, Nannong will be the exclusive supporter of WSAVA’s participation in the upcoming Animals Asia/WSAVA Pain Symposium, to be held in Chengdu, China, later this year. The event is designed to provide continuing education opportunities for veterinary professionals and to highlight the importance of evidence-based approaches to pain management.
“We are delighted to welcome Nannong to the WSAVA global community,” said WSAVA President Dr. Jim Berry. “Their support reflects a shared commitment to advancing veterinary standards and improving animal care.”
Mr. Wang Rui, CEO of Nannong Animal Pharmaceuticals, stated: “As a leading authority in the global small animal veterinary field, WSAVA represents both an honor and a responsibility for Nannong Animal Pharmaceuticals to partner with. WSAVA’s core mission of advancing standardized clinical practices and elevating animal welfare deeply aligns with our corporate vision of ‘harnessing technology to safeguard animal health and enhance human well-being.’ Moving forward, we aim to collaborate with the WSAVA platform to introduce more international courses on pain management and animal welfare, jointly advance the standardization of clinical practices and public education initiatives, bridge the professional capabilities of Chinese veterinarians with global standards, and contribute to the advancement of animal health.”
Mr. Bao Lei, Head of Marketing and Medical Department at Nannong Animal Pharmaceuticals, added: “First, I would like to express my gratitude to WSAVA for awarding me the 2024 Animal Welfare Award. Our company’s philosophy is profoundly aligned with WSAVA’s commitment to ‘improving animal health and welfare,’ and this shared vision has driven our collaboration. In the field of perioperative management, Nannong Animal Pharmaceuticals consistently adheres to international clinical guidelines in our R&D efforts, with a current focus on building an evidence-based multimodal analgesia system. Through deeper collaboration with WSAVA, we aspire to integrate more evidence-based solutions into clinical pathways, fostering the convergence of companion animal healthcare standards in China with globally advanced systems.”
WSAVA’s partnerships with industry leaders play a vital role in enabling the association to deliver high-quality educational programs and to support the global veterinary profession. The addition of Nannong as a Bronze Partner strengthens these efforts and fosters greater collaboration in key areas of animal health.
We are proud to welcome Nannong Animal Pharmaceuticals to the WSAVA community and look forward to working together to advance companion animal care globally.
Welcome to the WSAVA Community!
For more information on the WSAVA Pain Management Committee and its initiatives, please visit: https://wsava.org/committees/global-pain-council/